Product Description

1B-LSD 125mcg Blotters

1B-LSD 125mcg Blotters(1-butanoyl-LSD) is a synthetic lysergamide and structural analog of LSD, featuring a butyryl group attached to the indole nitrogen (N1 position). It is primarily encountered as a “research chemical” or novel psychoactive substance (NPS), often sold on blotter paper (e.g., 125 mcg doses). It is not approved for medical use and has limited human data.

Pharmacology and Mechanism of Action

1B-LSD functions largely as a prodrug for LSD. In vitro and animal studies show that the N1-acyl substitution significantly reduces direct binding affinity and agonist activity at key receptors, particularly the serotonin 5-HT2A receptor (the primary mediator of classic psychedelic effects). For example, 1B-LSD exhibits roughly 36-fold lower affinity at 5-HT2A compared to LSD.

Once ingested, 1B-LSD undergoes rapid hydrolysis (deacylation) in vivo, releasing active LSD. This conversion explains its LSD-like behavioral effects in rodent models, such as the head-twitch response (HTR), a proxy for hallucinogenic activity. In mice, 1B-LSD is approximately one-third to one-seventh as potent as LSD on a molar basis.

LSD (and thus the effects of 1B-LSD after conversion) acts as a partial agonist at 5-HT2A receptors, with additional activity at other serotonin subtypes (e.g., 5-HT1A, 5-HT2C), dopamine receptors, and adrenergic sites. This leads to altered cortical glutamate release, changes in brain network connectivity (e.g., default mode network disruption), and the characteristic perceptual, emotional, and cognitive effects of psychedelics.

Pharmacokinetics: Limited direct human data exist for 1B-LSD, but studies on close analogs like 1P-LSD show rapid conversion to LSD after oral administration, with near-complete bioavailability of the resulting LSD. LSD itself has an onset of 30–90 minutes, peaks around 2–3 hours, and lasts 8–12 hours, with a plasma half-life of roughly 3–5 hours. Similar profiles are expected for 1B-LSD.

Subjective Effects

User reports and animal data suggest effects highly similar to LSD, including visual distortions, altered thought patterns, time dilation, euphoria or anxiety, and potential ego dissolution at higher doses. The 125 mcg blotter strength is a common recreational/research dose, roughly comparable in potency to a moderate LSD dose after conversion (though individual hydrolysis efficiency may vary). Onset and duration are expected to align closely with LSD.

Safety Profile

Physiological safety of LSD is high at typical doses, with no documented direct fatal overdoses from LSD itself despite decades of use. The estimated lethal dose is extremely high (~100 mg, or ~1,000 times a standard recreational dose). Acute effects include modest increases in heart rate, blood pressure, and body temperature, pupil dilation, and possible nausea or jaw tension.

For 1B-LSD specifically, safety data are sparse. In silico (computer-predicted) toxicology assessments flag moderate potential hematotoxicity and some cardiotoxicity (hERG channel inhibition) risks, similar to other N1-acylated analogs, though these are predictive and not confirmed in humans. Pulmonary or other organ risks are also modeled but unverified clinically.

Primary risks are psychological and behavioral:

• Acute anxiety, panic, paranoia, or “bad trips.”
• Potential precipitation or exacerbation of underlying mental health conditions (e.g., psychosis, schizophrenia vulnerability).
• Hallucinogen Persisting Perception Disorder (HPPD) — rare persistent visual disturbances.
• Impaired judgment leading to accidents or risky behavior.

Unknowns and caveats: As a research chemical, purity, exact dosing, and long-term effects are uncertain. Variability in hydrolysis could lead to inconsistent LSD exposure. Interactions with other substances (e.g., SSRIs, stimulants, alcohol) are poorly studied but could increase risks. There are no established medical uses, and it is not equivalent to regulated pharmaceuticals.

Legal status varies: unscheduled in some jurisdictions but may fall under analog acts if intended for human consumption; controlled or banned in others (e.g., under psychoactive substances laws in the UK).

Bottom line: 1B-LSD appears to exert its effects primarily via metabolic conversion to LSD, producing a similar pharmacological and experiential profile with somewhat lower potency. While LSD has a reputation for low physiological toxicity, 1B-LSD carries uncertainties due to limited human research, potential impurities, and predicted toxicological signals. Use involves significant legal, health, and psychological risks. This exploration is for informational purposes only and does not encourage consumption. Consult scientific literature and healthcare professionals for any related concerns.

Additional Information